Cetuximab: The Emerging Evidence of its Therapeutic Value in Squamous Cell Carcinoma of the Head and Neck.

Bibliographic Details
Title: Cetuximab: The Emerging Evidence of its Therapeutic Value in Squamous Cell Carcinoma of the Head and Neck.
Authors: Ayoola, Ayodele1, Yixing Jiang1, Belani, Chandra P.1 cbelani@psu.edu
Source: Clinical Medicine Reviews in Oncology. May2010, Issue 2, p221-229. 9p.
Subject Terms: *CETUXIMAB, *SQUAMOUS cell carcinoma, *DISEASES, *CANCER, *DRUG therapy
Abstract: The worldwide incidence of head and neck cancer exceeds half a million cases annually with squamous-cell histology as the most predominant. Almost half of newly diagnosed cases have advanced disease at diagnosis. The high morbidity and mortality associated with the malignancy has brought more attention to this cancer. The improvement in the diagnosis and management has resulted in considerable improvements in quality of life and survival. EGFR is constitutively expressed in squamous-cell carcinoma of the head and neck (SCCHN) paving the path for evaluation of EGFR targeted agents. Cetuximab is a chimeric monoclonal antibody that targets the extracellular epitope in the EGFR ligand-binding domain. It was initially approved by the Food and Drug Administration, FDA, in 2006 for use in SCCHN in combination with radiation therapy based on improvement in both locoregional control and survival. In addition, it is efficacious as a single agent in patients with failure after prior platinum-based chemotherapy and is also indicated in combination with platinum-based chemotherapy in first-line recurrent or metastatic SCCHN. This paper reviews the mechanism of action, clinical studies, safety and efficacy of cetuximab in SCCHN. [ABSTRACT FROM AUTHOR]
Copyright of Clinical Medicine Reviews in Oncology is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
More Details
ISSN:11792531
DOI:10.4137/cmro.s4601
Published in:Clinical Medicine Reviews in Oncology
Language:English